



**For Immediate Release**

**March 19, 2019**

**PAIN THERAPEUTIC CMX-020 ACHIEVES CLINICAL TESTING MILESTONES AS A POTENTIAL REPLACEMENT FOR INTRAVENOUS OPIOIDS**

Milwaukee... Cmxtwenty is pleased to announce that it has successfully completed a Phase 1 maximum tolerated dose (MTD) human clinical study in Australia with its novel intravenous drug, CMX-020. The human dose levels reached in this MTD safety study are equivalent to levels in animal studies which provide a degree of efficacy comparable to a high dose of remifentanyl, a powerful opioid used during surgery. However, this CMX-020 dose level does not exhibit the serious side effects of opioids that include death due to respiratory depression, or other opioid related side effects such as addiction, euphoria/dysphoria, nausea, itching, dizziness, constipation, and fatigue.

There were 49,068 deaths from opioids in 2017, more than the number of deaths due to traffic accidents (CDC January 2019). Additionally, there may be more than 20,000 yearly deaths and increased per patient costs of \$7,000 associated with the 7.3 million inpatient surgical and endoscopic procedures as a result of using opioids in US hospitals (Shafi et al, JAMA May 23, 2018). Lane Brostrom, Ph.D., Cmxtwenty CEO, says “Hospitals and doctors are not at fault – opioids are often the only analgesic strong enough to manage acute surgical and cancer pain in hospitals. Clearly, there is an unmet need for an intravenous non-narcotic pain therapy comparable to that of opioids, but without their serious and sometimes lethal side effects.”

With a half-life of 45 minutes, intravenous CMX-020 could be utilized in operative settings or in post-operative settings with scheduled or patient-controlled analgesia. A Phase 2 human clinical study utilizing intravenous CMX-020 for pain associated with hip replacement is in the planning stages.

Cmxtwenty also has an oral version of CMX-020 in Phase 2 development. In addition to its favorable non-opioid characteristics, oral CMX-020, unlike acetaminophen, is not toxic to the liver.

Overall, CMX-020 is a novel non-narcotic therapeutic that produces its analgesic effects through multiple pain pathway receptors. CMX-020 can be delivered intravenously or orally with the potential to greatly reduce the use of prescription opioids.

**About Cmxtwenty** – Cmxtwenty is an angel-funded Milwaukee, Wisconsin based pharmaceutical company focused on development of a first-in-class non-narcotic treatment for pain. CMX-020 originated from research published by the Medical College of Wisconsin.

**For further information** – Visit the company website at [www.cmxtwenty.com](http://www.cmxtwenty.com), or to schedule an interview, contact Steve Lyons at [slyons@sjlgroup.com](mailto:slyons@sjlgroup.com)

#30#